Letter from the Editor

Dear Reader, The 2019 American College of Cardiology Scientific Session was a robust and dynamic meeting packed with innovative research, groundbreaking science, and interactive education. Late Breaking Science including the results of DECLARE-TIMI 58, which extended the benefits of SGLT2 inhibition beyond patients with diabetes and established cardiovascular disease to those with risk factors; new data establishing the efficacy and safety of TAVR vs SAVR for low-risk patients; and data demonstrating the use of the Apple Watch for detection of atrial fibrillation shared the spotlight with many other innovative sessions. In the following pages, you will find a comprehensive review of this important meeting including topics such as primary prevention, diabetes, heart failure, vascular medic...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on 4 June, 2019